Clinical Tumor Anemia Registry (TAR)

iOMEDICO AG1,018 enrolled

Overview

The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.

Study Type

OBSERVATIONAL

Enrollment

1,018

Conditions

Anemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed malignant disease * Hemoglobin level \< 11 g/dl (female) or \< 12 g/dl (male) * Start of antianemic therapy no more than 7 days prior to informed consent * Performance status 0 - 3 (Karnofsky-Index \>= 40%) * Minimum age: 18 years * Informed written consent Exclusion Criteria: * Hypersensitivity against antianemic therapies * Myelodysplastic Syndrome * Experimental antianemic therapy

Locations (1)

iOMEDICO

Freiburg im Breisgau, Germany

Outcomes

Primary Outcomes

Documentation of therapies

Overview on the current routine treatment of anemia in cancer patients in Germany

Time frame: 12 weeks per patient

Secondary Outcomes

Change in hemoglobin levels and QoL

Effectiveness of different antianemic treatments is investigated by measuring increase of hemoglobin levels and QoL (FACT-An and FACT-GP). Baseline in hemoglobin (before treatment) is compared with hemoglobin levels after treatment. Each patient is followed for a maximum of 12 weeks to obtain data about the course of the treatment.

Time frame: 12 weeks per patient

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.